Edition:
United Kingdom

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.50EUR
13 Dec 2017
Change (% chg)

€0.06 (+13.88%)
Prev Close
€0.44
Open
€0.45
Day's High
€0.53
Day's Low
€0.44
Volume
24,108,661
Avg. Vol
3,859,673
52-wk High
€0.54
52-wk Low
€0.40

Latest Key Developments (Source: Significant Developments)

Molmed Q3 net loss narrows to EUR 1.6‍​ mln
Monday, 6 Nov 2017 

Nov 6 (Reuters) - MOLECULAR MEDICINE SPA ::Q3 OPERATING REVENUE EUR ‍​6.2 MILLION VERSUS EUR 3.7 MILLION YEAR AGO.Q3 NET LOSS EUR 1.6‍​ MILLION VERSUS LOSS EUR 5.9 MILLION YEAR AGO.  Full Article

MolMed announces review of strategic agreement with GlaxoSmithKline
Thursday, 1 Sep 2016 

MolMed SpA : Announces amendment of strategic agreement signed with GlaxoSmithKline (GSK) on March 19, 2015 . Agreement relates to MolMed's supply of services for the clinical application of gene therapies based on viral vector cellular transduction until March 31, 2020 . To be eligible, through the 5 year-period covered by the contract, for minimum anticipated revenues of 48 million euros ($53.73 million) from prior 34 million euros .Of minimum anticipated revenues of 48 million euros, around 14 million euros have already been received.  Full Article

Molmed H1 net loss narrows to EUR 8.4 mln
Monday, 1 Aug 2016 

Molmed Spa : H1 total revenue 10.2 million euros ($11.39 million) versus 7.2 million euros a year ago .H1 net loss 8.4 million euros versus loss 11.2 million euros a year ago.  Full Article

Oxford BioMedica grants to MolMed non-exclusive licence under its LentiVector platform technology
Tuesday, 7 Jun 2016 

Molmed Spa : Signs with Oxford BioMedica new non-exclusive licence agreement concerning lentiviral vector technology . Oxford BioMedica grants to Molmed non-exclusive licence under its LentiVector platform technology for manufacturing and development services . At the same time, the parties terminated the agreement dated 10 December 2004 under which Oxford BioMedica granted MolMed a world-wide, exclusive licence on development and commercialisation of certain products in the field of genetically modified T lymphocytes transduced with retroviral vectors used in research and ex vivo gene therapy, including Zalmoxis .As a result of this agreement settlement, MolMed owes no outstanding royalties to Oxford BioMedica while keep using the above mentioned technology, in the ongoing development and potential commercialization of Zalmoxis.  Full Article

European Commission grants MolMed European marketing authorisation to Strimvelis
Monday, 30 May 2016 

MolMed SpA : European Commission grants MolMed European marketing authorisation to Strimvelis .The European Medicines Agency (EMA) has approved Strimvelis, an exvivo stem cell gene therapy to treat patients with ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency).  Full Article

Molmed Q1 net loss narrows to EUR 4.1 mln
Tuesday, 10 May 2016 

Molmed SpA : Q1 net loss 4.1 million euros ($4.67 million) versus loss 4.2 million euros a year ago . Q1 total operating revenue 5.3 million euros versus 2.7 million euros a year ago .Confirms the outlook already provided for FY 2016.  Full Article

MolMed SpA signs cooperation agreement with Genenta Science
Monday, 21 Mar 2016 

MolMed SpA:Signs agreement with Genenta Science on a multi-year cooperation to develop and manufacture a gene therapy product for the treatment of multiple myeloma.  Full Article

BRIEF-Molmed: Italian Medicines Agency Sets Price Of Reimbursement For Zalmoxis

* ITALIAN MEDICINES AGENCY SETS GROSS PRICE OF REIMBURSEMENT FOR ZALMOXIS AT EUR 149,000 PER INFUSION Source text for Eikon: Further company coverage: (Gdynia Newsroom)